Samsung and Alcedis Partner to Use Galaxy Watch Data for Clinical Trial Evidence
The collaboration seeks to turn continuous wearable biometrics into validated trial endpoints that could speed and lower the cost of drug studies.
Overview
- Samsung and German clinical research firm Alcedis announced the partnership on Wednesday to develop methods that convert Galaxy Watch sensor signals into clinical trial evidence.
- Samsung will supply watches, biometric sensors, and backend infrastructure while Alcedis will design studies, handle patient engagement, and ensure data meets medical research standards.
- Target signals named by the partners include bioelectrical impedance analysis, electrodermal activity, and medical-grade tracking for sleep apnea and atrial fibrillation.
- Work is now in methodology and pilot-planning stages focused on validating digital endpoints, securing informed user consent, and meeting regulatory standards, with no trial results published yet.
- The deal fits a broader industry shift toward remote, patient-centered trials and regulators will be key to whether wearable-derived endpoints are accepted for drug approval; early signs to watch are pilot protocols, validation studies, and regulatory engagement.